

DEC. 11. 2003 2:53PM GLAXO WELLCOME

RECEIVED
CENTRAL FAX CENTER

NO. 1657
DEC 11 2003



GlaxoSmithKline

OFFICIAL

FAX

To Group 1614

Company USPTO

Fax 703-872-9306

From Allyson K. Jacobs

Tel 919-483-9105 Fax 919-483-7988

E-mail akj27836@glaxowellcome.com

Date 11-Dec-2003 Pages including cover 12

Subject Serial No.: 10/669,400


Filing Date: 9/23/03

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Amendment Transmittal + copy
Amendment
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PU3552US2	
Applicant(s): Guterman et al.					
Serial No. 10/669,400	Filing Date 9/23/03	Examiner S. Patel	Group Art Unit 1624		
Invention: FORMULATIONS OF 5HT AGONISTS					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	23 -	20 =	3 x	\$18.00	\$54.00
INDEP. CLAIMS	2 -	3 =	0 x	\$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$54.00
<div style="margin-top: 20px;"><input type="checkbox"/> No additional fee is required for amendment. <input checked="" type="checkbox"/> Please charge Deposit Account No. 07-1392 in the amount of \$54.00 <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div>					
<div style="text-align: center;"> Signature</div> <p>John L. Lemanowicz, Reg. No. 37,380 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8247 Facsimile: (919) 483-7988</p>			Dated: 12/11/03		
cc:			<div style="border: 1px solid black; padding: 5px;"><p>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p><p style="text-align: center;">_____ Signature of Person Mailing Correspondence</p><p style="text-align: center;">_____ Typed or Printed Name of Person Mailing Correspondence</p></div>		

P11LARGE/REV08

RECEIVED
CENTRAL FAX CENTER

DEC 11 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In re Application of: Harris et al
Serial No.: 10/669400 Examiner: S. Patel
Filing Date: September 23, 2003 Art Unit: 1624
For: SUBSTITUTED AZA-OXINDOLE DERIVATIVES

Commissioner for Patents
Washington D.C. 20231

PRELIMINARY AMENDMENT

Sir:

This paper is submitted preliminary to examination and the calculation of filing fees. Entry of this preliminary amendment and early examination of the application is earnestly solicited.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.